Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Insmed IncorporatedNASDAQ: INSM

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q2 FY2026 gross profit of $358.27M rose 351.6% year over year, ahead of the +214.3% change in trailing-twelve-month gross profit. Sequentially, it rose 39.7% from the prior quarter. Over 3 fiscal years it compounded at +36.3% a year.

Context

  • Gross profit amounted to 79.4% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +351.6% holds above the trailing-twelve-month pace of +214.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$358.27M+39.7% QoQ
Last fiscal yearDec 2025
$481.55M+73.2% YoY
LTMJun 2026
$947.34M+214.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+351.6%——
1 year+73.2%——
3-year CAGR+36.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
481.55M USD
Year-over-year change
+73.2%
4-year CAGR
+35.2%

Gross Profit vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 gross profit of $947.34M is the 2nd highest of the 4 companies compared; the peer median is $416.98M.
  • Its year-over-year change of +214.3% is the 3rd highest of 4, against a peer median of +251.0%.
  • Gross profit amounts to 83.3% of revenue for INSM, versus a peer median of 86.1%.
INSM Competitors Peer median
Gross Profit for INSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$2.72B -0.8%+16.1%86.1%
INSMInsmed IncorporatedLTM Jun 2026$947.34M +214.3%+36.3%83.3%
LQDALiquidia CorporationLTM Jun 2026$416.98M +2967.4%+123.0%92.5%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$88.23M +251.0%—80.4%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding INSM) $416.98M+251.0%+69.6%86.1%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue188.46M245.36M305.21M363.71M606.42M
Cost of Revenue44.15M55.13M65.57M85.74M124.88M
Gross Profit144.31M190.23M239.64M277.97M481.55M
Gross Margin76.6%77.5%78.5%76.4%79.4%
Research & Development272.74M397.52M571.01M598.37M771.09M
Selling, General & Admin234.27M265.78M344.5M461.12M701.17M
Operating Expenses519.4M647.55M949.26M1.16B1.66B
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
EBITDA(383.65M)(447.37M)(660.18M)(818.79M)(1.17B)
EBITDA Margin-203.6%-182.3%-216.3%-225.1%-193.2%
Operating Income(375.09M)(457.32M)(709.63M)(878.25M)(1.18B)
Operating Margin-199.0%-186.4%-232.5%-241.5%-194.0%
Interest Income174K11.08M42.13M53.31M60.66M
Interest Expense40.47M26.45M81.69M84.91M83.8M
Other Income / Expenses(61.32M)(22.83M)(37.39M)(31.81M)(95.02M)
Income Before Tax(436.41M)(480.15M)(747.01M)(910.07M)(1.27B)
Pre-Tax Margin-231.6%-195.7%-244.8%-250.2%-209.7%
Income Tax Expense(1.76M)1.38M2.56M3.71M5.03M
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (Basic)(3.88)(3.91)(5.34)(5.57)(6.41)
EPS (Diluted)(3.88)(3.91)(5.34)(5.57)(6.41)
Weighted Avg Shares112.11M123.04M140.43M164.04M213.64M
Weighted Avg Shares (Diluted)112.11M123.04M140.43M164.04M213.64M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.